Table 1.
Baseline Characteristics, by Body Mass Index (BMI)
| Characteristic | Overall (n = 246) | Underweight (n = 19) | Normal Weight (n = 163) | Overweight/Obese (n = 64) | P Value |
|---|---|---|---|---|---|
| Female sex | 135 (50) | 11 (55) | 86 (48) | 38 (54) | .66 |
| Race | .004 | ||||
| Asian | 61 (23) | 10 (50) | 40 (22) | 11 (15) | |
| Black | 144 (53) | 10 (50) | 96 (54) | 38 (54) | |
| White | 29 (11) | 0 | 15 (8) | 14 (20) | |
| Other | 36 (13) | 0 | 28 (16) | 8 (11) | |
| Age, y | 35 (29–41) | 34 (30–37) | 34 (29–40) | 38 (31–43) | .03 |
| CD4+ T-cell count, cells/µL | 179 (90–229) | 118 (50–223) | 183 (87–227) | 175 (119–240) | .06 |
| Plasma HIV RNA load, log10 copies/mL | 5.07 (4.57–5.47) | 5.28 (5.00–5.58) | 5.07 (4.64–5.46) | 4.91 (4.34–5.57) | .09 |
| Hemoglobin level, mg/dL | 12.4 (10.9–13.8) | 10.5 (9.7–11.6) | 12.5 (11.1–13.8) | 12.5 (11.1–13.9) | .001 |
| Albumin level, mg/mL | 4.0 (3.6–4.3) | 3.6 (3.1–4.0) | 3.9 (3.6–4.2) | 4.1 (3.8–43.0) | .01 |
| ART regimen | .90 | ||||
| EFV + 3TC-ZDV | 99 (37) | 7 (35) | 69 (39) | 23 (32) | |
| EFV + FTC-TDF | 89 (33) | 7 (35) | 56 (31) | 26 (37) | |
| ATV + DDI + FTC | 82 (30) | 6 (30) | 54 (30) | 22 (31) | |
| Country | <.001 | ||||
| Brazil | 29 (12) | 1 (5) | 16 (10) | 12 (19) | |
| Haiti | 30 (12) | 5 (26) | 20 (12) | 5 (8) | |
| India | 26 (11) | 8 (42) | 14 (9) | 4 (6) | |
| Malawi | 26 (11) | 2 (11) | 19 (12) | 5 (8) | |
| Peru | 28 (11) | 0 | 24 (15) | 4 (6) | |
| South Africa | 28 (11) | 0 | 18 (11) | 10 (16) | |
| Thailand | 28 (11) | 1 (5) | 21 (13) | 6 (9) | |
| United States | 24 (10) | 0 (0) | 10 (6) | 14 (22) | |
| Zimbabwe | 27 (11) | 2 (11) | 21 (13) | 4 (6) |
Data are no. (%) of subjects or median value (interquartile range). BMI was calculated as the weight in kilograms divided by the height in meters squared and categorized as underweight (<18.5), normal (18.5–24.9), overweight (>25–29.9), and obese (≥30) [31].
Abbreviations: ART, antiretroviral treatment; ATV, atazanavir; DDI, didanosine; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus type 1; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine; 3TC, lamivudine.